NORTHVALE, N.J.--(BUSINESS WIRE)--June 27, 2006--Elite Pharmaceuticals, Inc. ("Elite" or the Company") (AMEX: ELI - News) has successfully completed a second pilot Phase I pharmacokinetic study evaluating the Company's ELI-154, a once-daily oxycodone HCl. This patent pending product is intended to deliver more consistent levels of the drug to patients who take the drug for chronic pain. Currently, there is no once-daily oxycodone on the market.
